Imricor logs minimal revenue as U.S. commercial launch begins

Imricor reported minimal revenue for the first half of its 2026 financial year while announcing progress on U.S. regulatory clearances for its MRI-guided cardiac ablation technology. In its results presentation and earnings call, the company said additional Food and Drug Administration clearances had been obtained, allowing it to begin commercial activity in the United States. Revenue in the period remained very small, reflecting the early stage of the launch and the limited number of installed sites. Imricor's business model depends on hospitals adopting interventional MRI suites, which requires capital investment and clinical training, making the pace of revenue ramp-up a key uncertainty for the company.